Drug intelligence / Profile preview

GB-AOS5

Development stage: Preclinical
Lead developer: GlycosBio
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Vaginal

Overview

GB-AOS5 is a preclinical-stage therapeutic candidate being developed by GlycosBio for the treatment of post-menopausal vaginal dryness. It utilizes the company's proprietary Activated Oil System (AOS), a lipid-based delivery platform designed to enhance the stability and efficacy of bioactive lipids. The AOS technology aims to provide a non-hormonal alternative for managing symptoms of vulvovaginal atrophy by restoring the natural lipid barrier and improving tissue hydration. As of 2024, the program is in preclinical development, with the sponsor indicating it is approaching clinical stages.

Beyond the preview

Go deeper on GB-AOS5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB-AOS5.

Explore the full profile